Subchronic Effects of Olanzapine on Sleep EEG in Schizophrenic Patients with Predominantly Negative Symptoms

Background: It is well known that sleep disturbance is an integral symptom of schizophrenia. In recent studies, a deficit of delta sleep has been observed in schizophrenic patients. Antipsychotic drugs with serotonin (5-HT₂) receptor-antagonistic properties are considered to have delta sleep promoting effects. We have investigated the effects of subchronic olanzapine treatment on sleep EEG in schizophrenic patients. Methods: The effects of administration of olanzapine (15 to 20 mg) on sleep were studied for four weeks in 10 male, drug-free patients suffering from schizophrenia with predominantly negative symptoms. Conventional sleep EEG parameters were investigated at baseline and after treatment with olanzapine for four weeks. Additionally, spectral power analysis of the EEG signal in distinct frequency bands was computed for different sleep stages. Psychopathology (PANSS, HAMD-17, HAMA) and side effects were assessed weekly. Results: All patients improved, as measured by PANSS global scores. Compared to baseline, there was a significant improvement of parameters of sleep efficiency and an increase of delta sleep as well as REM sleep. Regarding spectral power values, no significant differences between baseline and treatment conditions were found. Conclusions: Sleep improvement was due to parameters of sleep efficiency and delta sleep, which may be related to serotonin antagonistic properties of olanzapine.

References

• 1 American Psychiatric A ssociation. Diagnostic and Statistical Manual of Mental Disorders. 4th ed Washington, DC; American Psychiatric Press 1994
• 2 Baptista T, Kin N M, Beaulieu S, de Baptista E A. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.  Pharmacopsychiatry. 2002;  35 205-219
• 3 Benca R M, Obermeyer W H, Thisted R A, Gillin J C. Sleep and psychiatric disorders. A meta-analysis.  Arch Gen Psychiat. 1992;  49 651-668
• 4 Borbély A, Trachsel L, Tobler I. Effects of ritanserine on sleep stages and sleep EEG in the rat.  Eur J Pharmacol. 1988;  156 275-278
• 5 Bymaster F P, Calligaro D O, Falcone J F, Marsh R D, Moore N A, Tye N C, Seeman P, Wong D T. Radioreceptor binding profile of the atypical antipsychotic olanzapine.  Neuropsychopharmacology. 1996;  14 87-96
• 6 Driver H S, Flanigan M J, Bentley A J, Luus H G, Shapiro C M, Mitchel D. The influence of ipsapirone, a 5-HT_1A agonist, on sleep patterns of healthy subjects.  Psychopharmacology. 1995;  117 186-192
• 7 Dugovic C, Wauquier A, Janssen P A. Differential effects of the new antipsychotic risperidone on sleep and wakefulness in the rat.  Neuropharmacology. 1989;  28 1431-1433
• 8 Eschweiler G W, Bartels M, Langle G, Wild B, Gaertner I, Nickola M. Heart-rate variability (HRV) in the ECG trace of routine EEGs: fast monitoring for the anticholinergic effects of clozapine and olanzapine?.  Pharmacopsychiatry. 2002;  35 96-100
• 9 Feinberg I, Braum N, Koresko R L, Gottlieb F. Stage 4 sleep in schizophrenia.  Arch Gen Psychiat. 1969;  21 262-266
• 10 Frieboes R -M, Murck H, Antoijevic I, Kraus T, Hinze-Selch D, Pollmächer T, Steiger A. Characterization of the sigma ligand panamesine, a potential antipsychotic, by immune response in patients with schizophrenia and by sleep-EEG changes in normal controls.  Psychopharmacology. 1999;  141 107-110
• 11 Ganguli R, Reynolds C F, Kupfer D J. EEG sleep in young, never medicated, schizophrenic patients: a comparison with delusional and nondelusional depressives and with healthy controls.  Arch Gen Psychiat. 1987;  44 36-45
• 12 Hiatt J F, Floyd T C, Katz P H, Feinberg I. Further evidence of abnormal NREM sleep in schizophrenia.  Arch Gen Psychiat. 1985;  42 797-802
• 13 Hinze-Selch D, Mullington J, Orth A, Lauer C J, Pollmächer T. Effects of clozapine on sleep: a longitudinal study.  Biol Psychiat. 1997;  42 260-266
• 14 Idzikowski C, Mills F J, Glennard R. 5-Hydroxytryptamine-2 antagonist increases human slow wave sleep.  Brain Res. 1986;  378 164-168
• 15 Keshavan M S, Reynolds C F, Kupfer D J. Electroencephalographic sleep in schizophrenia: a critical review.  Compr Psychiat. 1990;  31 34-37
• 16 Kupfer D J, Wyatt R J, Scott J, Snyder F. Sleep disturbance in acute schizophrenic patients.  Am J Psychiat. 1970;  126 1213-1223
• 17 Lewis C F, Tandon R, Shipley J E, DeQuardo J R, Jibson M, Taylor S F, Goldman M. Biological predictors of suicidality in schizophrenia.  Acta Psychiat Scand. 1996;  94 416-420
• 18 Mason S L, Reynolds G P. Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue.  Eur J Pharmacol. 1992;  221 397-398
• 19 Rechtschaffen A, Kales A. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. Washington, DC: Superintendent of Documents, U.S. Government Printing Office 1968
• 20 Riemann D, Hohagen F, Fleckenstein P, Schredl M, Berger M. The cholinergic REM induction test with RS86 after scopolamine treatment in healthy subjects.  Psychiat Res. 1991;  38 247-260
• 21 Riemann D, Hohagen F, Krieger S, Gann H, Müller W E, Olbrich R, Wark H J, Bohus M, Low H, Berger M. Cholinergic REM induction test: muscarinic supersensitivity underlies polysomnographic findings in both depression and schizophrenia.  J Psychiat Res. 1994;  28 195-210
• 22 Salin-Pascual R J, Herrera-Estrella M, Galicia-Polo L, Laurrabaquio M. Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency.  Biol Psychiat. 1999;  46 141-143.
• 23 Sanger T M, Liebermann J A, Tohen M, Grundy S, Beasley C J r, Tollefson G D. Olanzapine versus haloperidol treatment in first-episode psychosis.  Am J Psychiat. 1999;  156 79-87
• 24 Schuld A, Kühn M, Haack M, Kraus T, Hinze-Selch D, Lechner C, Pollmächer T. A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia.  Pharmacopsychiatry. 2000;  33 109-111
• 25 Sharpley A L, Vassallo C M, Cowen P J. Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT_2C receptors in vivo.  Biol Psychiat. 2000;  47 468-470
• 26 Stern M, Fram D, Wyatt R, Grinsponn L, Tursky B. All night sleep studies of acute schizophrenics.  Arch Gen Psychiat. 1969;  20 470-477
• 27 Tandon R, Shipley J E, Taylor S, Greden J F, Eiser A, DeQuardo J, Goodson J. Electroencephalographic sleep abnormalities in schizophrenia. Relationship to positive/negative symptoms and prior neuroleptic treatment.  Arch Gen Psychiat. 1992;  49 185-194
• 28 Tollefson G D, Beasley C M, Tran P V, Street J S, Krueger J A, Tamura R N, Graffeo K A, Thieme M E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective disorders: results of an international collaborative trial.  Am J Psychiat. 1997;  154 457-456
• 29 Tollefson G D, Sanger T M. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol controlled trial with olanzapine.  Am J Psychiat. 1997;  154 466-474
• 30 Tollefson G D, Sanger T M, Lu Y, Thieme M E. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.  Arch Gen Psychiat. 1998;  55 250-258
• 31 Virkkunen M, Wahlbeck K, Rissanen A, Naukkarinen H, Franssila-Kallunki A. Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study.  Pharmacopsychiatry. 2002;  35 124-126
• 32 Wetter T C, Lauer C J, Gillich G, Pollmächer T. The electroencephalographic sleep pattern in schizophrenic patients treated with clozapine or classical antipsychotic drugs.  J Psychiat Res. 1996;  30 411-419